Posts

Wave aims for monthly dosing with RNA editing treatment for AATD now targets a monthly injection schedule for its WVE‑006 program in AATD.

Wave Life Sciences is advancing an investigational RNA editing therapy, WVE-006, for alpha‑1 antitrypsin deficiency (AATD) with the goal of enabling monthly subcutaneous dosing. Sources: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype ... Sanofi, Wave post updates in race to end AATD's 40-year drought Wave Life Sciences' RNA Editing Therapy Shows Promising R... RNA editing for the treatment of alpha-1 antitrypsin deficiency - PMC RNA Editing Therapy Shows Positive Proof-of-Mechanism Results ... Wave Crashes Despite Successful RNA Editing in AATD Study RNA Single-base Editing Therapy that Treats Genetic Lung and ... Wave Life Sciences Announces Data From 200 Mg Single ... Study Details | NCT06405633 | A Phase 1b/2a, Open-label Single ... Wave shares sink on new study results for RNA editing drug New Data - March 26,2026 Reimagining RNA medicine [PDF] RNA Editing for the Treatment of Alpha-1 Antitrypsin Deficiency ... Wave Life Sciences Annou...

TrumpRx adds more than 600 generic meds, building on one success in US pricing

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease

Zydus Lifesciences to Pursue Acquisitions in Specialty and Rare Diseases

Takeda faces possible $2.5 billion damages in Amitiza pay‑for‑delay case

Akeso Spotlights AML Data for Anti‑CD47 mAb Ahead of EHA 2026

BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test

Relay presses ahead on PI3Kα inhibitor after first phase 2 data in vascular (blood vessel) disorder

SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting

Clinical trial flaws being scaled, not solved by AI: report

Incyte inks deal with Edison Scientific to train AI through drug discovery

Full-Life Technologies Raises $150M to Accelerate Clinical Assets and Manufacturing

AstraZeneca wins FDA nod for first‑in‑class blood pressure pill Baxfendy